A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

ConclusionsThe RP2D of sapanisertib in East Asian patients (3 mg QD) was lower than in Western patients (4 mg QD), but the pharmacokinetics and safety profiles were similar. Sapanisertib was well tolerated and showed moderate anti-tumor effects in heavily pretreated patients with nonhematologic malignancies.NCT NumberNCT03370302; Registered December 7, 2017

http://link.springer.com/10.1007/s11523-021-00855-w

Source: Targeted Oncology - November 29, 2021 Category: Cancer & Oncology Source Type: research